医用耗材智能装备

Search documents
迈得医疗股价涨5.79%,国泰基金旗下1只基金重仓,持有20万股浮盈赚取22.6万元
Xin Lang Cai Jing· 2025-09-16 02:16
9月16日,迈得医疗涨5.79%,截至发稿,报20.66元/股,成交5664.83万元,换手率1.69%,总市值34.34 亿元。 资料显示,迈得医疗工业设备股份有限公司位于浙江省玉环市沙门镇滨港工业城,成立日期2003年3月 10日,上市日期2019年12月3日,公司主营业务涉及医用耗材智能装备的研发、生产、销售和服务。主 营业务收入构成为:安全输注类连线机42.18%,血液净化类连线机37.90%,安全输注类单机14.04%, 其他类5.87%。 从基金十大重仓股角度 数据显示,国泰基金旗下1只基金重仓迈得医疗。国泰聚利价值定期开放灵活配置混合(005746)二季 度持有股数20万股,占基金净值比例为1.08%,位居第八大重仓股。根据测算,今日浮盈赚取约22.6万 元。 程瑶累计任职时间4年71天,现任基金资产总规模19.21亿元,任职期间最佳基金回报14.74%, 任职期 间最差基金回报3.78%。 国泰聚利价值定期开放灵活配置混合(005746)成立日期2018年3月27日,最新规模2.73亿。今年以来 收益5.47%,同类排名6623/8174;近一年收益10.46%,同类排名6881/7982;成 ...
迈得医疗股价跌5.07%,融通基金旗下1只基金位居十大流通股东,持有259.98万股浮亏损失270.38万元
Xin Lang Cai Jing· 2025-08-27 06:56
8月27日,迈得医疗跌5.07%,截至发稿,报19.47元/股,成交2.68亿元,换手率8.07%,总市值32.36亿 元。 融通健康产业灵活配置混合A/B(000727)基金经理为万民远。 资料显示,迈得医疗工业设备股份有限公司位于浙江省玉环市沙门镇滨港工业城,成立日期2003年3月 10日,上市日期2019年12月3日,公司主营业务涉及医用耗材智能装备的研发、生产、销售和服务。主 营业务收入构成为:安全输注类连线机42.18%,血液净化类连线机37.90%,安全输注类单机14.04%, 其他类5.87%。 从迈得医疗十大流通股东角度 数据显示,融通基金旗下1只基金位居迈得医疗十大流通股东。融通健康产业灵活配置混合A/B (000727)一季度减持156股,持有股数259.98万股,占流通股的比例为1.56%。根据测算,今日浮亏损 失约270.38万元。 融通健康产业灵活配置混合A/B(000727)成立日期2014年12月25日,最新规模20.74亿。今年以来收益 23.63%,同类排名3072/8194;近一年收益47%,同类排名2642/7963;成立以来收益198.7%。 责任编辑:小浪快报 截至发 ...
迈得医疗: 天健会计师事务所(特殊普通合伙)关于迈得医疗工业设备股份有限公司2024年年度报告的信息披露监管问询函的专项说明
Zheng Quan Zhi Xing· 2025-07-03 16:27
Main Business - The company's main products include safety infusion devices and blood purification equipment, with significant revenue declines in safety infusion single machines and blood purification single machines, down 39.59% and 100.00% respectively, while blood purification continuous machines saw substantial growth [2][5][6] - The first major customer accounted for a significant portion of annual sales, with the increase in transaction amount attributed to the growth in the blood purification product business and the overall industry [2][14] Supplier Information - The company sources all standard parts externally, with a mix of self-manufactured, custom procurement, and outsourced processing for non-standard components. The total procurement amount for 2024 was 23,959.42 million yuan, a decrease of 36.99% compared to the previous year [28][29] Inventory and Contract Liabilities - The company reported that the inventory of blood purification single machines remained unsold due to production cycle delays and customer facility issues, impacting revenue recognition [11][12] - The company maintains a production model based on order fulfillment, which has led to fluctuations in sales revenue for blood purification single machines [11][12] Accounts Receivable and Long-term Receivables - The company provided details on its top five customers, including transaction amounts and payment conditions, indicating a healthy receivables situation with good recovery rates [13][15] Goodwill Impairment - There were no indications of impairment for the company's assets, as the net realizable value of blood purification single machines exceeded their costs, negating the need for inventory write-downs [12][25] Construction in Progress - The company has invested in the development of its contact lens manufacturing subsidiary, with a focus on material research and production line construction, indicating a strategic expansion into the optical sector [3][24] Market Trends - The blood dialysis medical device market in China is projected to grow steadily, with a compound annual growth rate of 5.67% from 2019 to 2023, expected to reach 51.515 billion yuan by 2030 [6][14] - The company is also expanding into the contact lens market, which is anticipated to grow significantly, with the transparent and colored contact lens markets projected to reach 161 billion yuan and 183 billion yuan respectively by 2030 [18][20]
迈得医疗收盘上涨1.67%,最新市净率3.09,总市值24.28亿元
Sou Hu Cai Jing· 2025-06-03 11:10
Company Overview - Maide Medical's stock closed at 14.61 yuan, up 1.67%, with a latest price-to-book ratio of 3.09, marking a new low in 231 days, and a total market capitalization of 2.428 billion yuan [1] - As of the first quarter of 2025, five institutions held shares in Maide Medical, including three funds, one other entity, and one social security fund, with a total holding of 15.2835 million shares valued at 179 million yuan [1] - The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with main products including safety infusion and blood purification devices [1] Performance Metrics - For the first quarter of 2025, Maide Medical reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87%, and a net profit of -10,797,370.24 yuan, a year-on-year decline of 202.70%, with a gross profit margin of 32.89% [1] - The company's price-to-earnings ratio (TTM) is -58.81, and the static PE is -121.54, with a market capitalization of 2.428 billion yuan [2] - The industry average PE (TTM) is 60.04, and the industry median is 49.67, indicating that Maide Medical's valuation metrics are significantly lower than the industry averages [2]
迈得医疗收盘上涨3.47%,最新市净率2.97,总市值23.32亿元
Sou Hu Cai Jing· 2025-05-28 11:36
Core Viewpoint - MaiDe Medical's stock closed at 14.03 yuan, up 3.47%, with a latest price-to-book ratio of 2.97, marking a new low in 156 days, and a total market capitalization of 2.332 billion yuan [1] Group 1: Company Overview - MaiDe Medical Industrial Equipment Co., Ltd. specializes in the research, development, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main products include safety infusion and blood purification equipment [1] - The company has been recognized with qualifications such as the establishment of a postdoctoral workstation in Zhejiang Province and participation in various provincial projects [1] Group 2: Financial Performance - As of the first quarter of 2025, the company reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87% [1] - The net profit for the same period was -10,797,370.24 yuan, reflecting a year-on-year decline of 202.70% [1] - The sales gross margin stood at 32.89% [1] Group 3: Institutional Holdings - As of the first quarter of 2025, five institutions held shares in MaiDe Medical, including three funds, one other institution, and one social security fund, with a total holding of 15.2835 million shares valued at 17.9 million yuan [1]
迈得医疗收盘下跌2.46%,最新市净率2.12,总市值17.80亿元
Sou Hu Cai Jing· 2025-04-16 12:27
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Maide Medical, indicating a significant decline in revenue and profit for the third quarter of 2024 [1] - As of September 30, 2024, Maide Medical has 4,462 shareholders, an increase of 520 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and service of medical consumables and intelligent equipment, with key products in safety infusion and blood purification [1] Group 2 - The latest financial results show that Maide Medical achieved an operating income of 220 million yuan, a year-on-year decrease of 33.45%, and a net profit of 7.63 million yuan, down 89.37% year-on-year, with a gross profit margin of 48.86% [1] - The company's current price-to-earnings ratio (TTM) is -90.14, and the price-to-book ratio is 2.12, with a total market capitalization of 1.78 billion yuan [2] - Compared to industry averages, Maide Medical's financial metrics are significantly lower, with the industry average P/E ratio at 59.86 and average price-to-book ratio at 4.03 [2]